ArticleCell communication and signaling : CCS2026
A dual role of PIEZO2 in neuropathic pain: driving peripheral sensitization and enabling mechanical loading-induced analgesia.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMechanotherapy, a form of mechanical loading (ML), effectively relieves tactile allodynia-associated neuropathic pain by targeting sensitization points stimulated by PIEZO2, a mechanosensitive ion channel. However, the molecular mechanisms underlying peripheral sensitization and ML-induced analgesia remain unclear. The study aimed to investigate the role of PIEZO2 in neuroinflammatory processes in a rat model of chronic compression injury (CCD) of dorsal root ganglia (DRG).
methodsMechanical allodynia was assessed via paw withdrawal threshold in male Sprague-Dawley rats. ML was applied at intensities of 2.5-5 N, targeting either sensitization or non-sensitization points, with or without intrathecal administration of the PIEZO2 channel blocker D-GsMTx4. Behavioral assays, patch-clamp electrophysiology, western blot, enzyme-linked immunosorbent assay, RNA sequencing, and non-targeted metabolomics of skin, DRG, and spinal dorsal horn (SDH) were performed to evaluate neuronal excitability, inflammatory markers, and omics-level responses.
resultsCCD upregulates PIEZO2 expression in all tissues, indicating mechanical hypersensitivity and neuroinflammation. ML alleviates allodynia while suppressing SDH inflammation and MAPK signaling, especially at 5 N. Functionally blocking PIEZO2 attenuates ML-induced analgesia and downregulates rectifier K⁺ currents in DRG neurons. ML and the inhibition of PIEZO2 function exhibit similar lipid metabolism profiles and downregulate PGE₂ and all-trans-5,6-epoxyretinoic acid.
conclusionsPIEZO2 is essential for peripheral sensitization, as well as ML-induced analgesia, anti-inflammatory, and ion-channel-modulating effects, which may inform the development of novel non-pharmacological strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.